Sarepta Therapeutics Inc
XMUN:AB3A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sarepta Therapeutics Inc
XMUN:AB3A
|
US |
|
E
|
EDP Renovaveis SA
F:EDW
|
ES |
|
Grindrod Ltd
OTC:GRDLY
|
ZA |
|
D
|
Dollar Tree Inc
DUS:DT3
|
US |
|
B
|
Bank of Montreal
XMUN:BZZ
|
CA |
|
C
|
CSE Global Ltd
F:XCC
|
SG |
|
N
|
NioCorp Developments Ltd
XBER:BR3
|
US |
|
E
|
eBay Inc
DUS:EBA
|
US |
|
I
|
Indocement Tunggal Prakarsa Tbk PT
SWB:ITP
|
ID |
|
K
|
Konami Group Corp
SWB:KOA
|
JP |
|
K
|
KeyCorp
F:KEY
|
US |
|
R
|
Rockhopper Exploration PLC
F:R4Y
|
UK |
|
C
|
Cadence Design Systems Inc
SWB:CDS
|
US |
|
R
|
Relx PLC
DUS:RDEB
|
UK |
Wall St Price Targets
AB3A Price Targets Summary
Sarepta Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AB3A is 20.04 EUR with a low forecast of 4.39 EUR and a high forecast of 34.7 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AB3A's stock price target?
Price Target
20.04
EUR
According to Wall Street analysts, the average 1-year price target for AB3A is 20.04 EUR with a low forecast of 4.39 EUR and a high forecast of 34.7 EUR.
What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-4%
Over the last 13 years, the compound annual growth rate for Revenue has been 37%. The projected CAGR for the next 8 years is -4%.
What is the Gross Profit forecast for Sarepta Therapeutics Inc?
Projected CAGR
-2%
The compound annual growth rate for Gross Profit over the next 8 years is -2%.
